Richard Riedel
Overview:
Novel therapies for soft tissue and bone sarcomas
Positions:
Associate Professor of Medicine
Medicine, Medical Oncology
School of Medicine
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
M.D. 2000
Thomas Jefferson University
Resident in Medicine, Medicine
Duke University
Fellow in Hematology-Oncology, Medicine
Duke University
Fellow in Hematology-Oncology, Medicine
Duke University
Grants:
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Administered By
Duke Cancer Institute
Awarded By
Blueprint Medicines Corporation
Role
Principal Investigator
Start Date
End Date
Dissecting Mechanisms of Metastasis Through Comparative Systems Genetics
Administered By
Radiation Oncology
Awarded By
National Institutes of Health
Role
Investigator
Start Date
End Date
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Administered By
Duke Cancer Institute
Awarded By
SpringWorks Therapeutics
Role
Principal Investigator
Start Date
End Date
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
Administered By
Duke Cancer Institute
Awarded By
Deciphera Pharmaceuticals, LLC
Role
Principal Investigator
Start Date
End Date
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of MB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Subjects Following First-line Systemic Anti-cancer Therapy
Administered By
Duke Cancer Institute
Awarded By
Immune Design Corp.
Role
Principal Investigator
Start Date
End Date
Publications:
Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board.
Ewing sarcoma (ES) is a malignant tumor of bone and soft tissue that most often occurs in adolescents and young adults. Despite an international coordinated approach, several nuances, discrepancies, and debates remain in defining the standard of care for treating ES. In this review, the authors leverage the expertise assembled by formation of the National Ewing Sarcoma Tumor Board, a multi-institution, multidisciplinary virtual tumor board that meets monthly to discuss complicated and challenging cases of ES. This report is focused on select topics that apply to the management of patients with newly diagnosed ES. The specific topics covered include indications for bone marrow aspirate and biopsy for initial evaluation compared with fluorodeoxyglucose-positron emission tomography, the role of interval compressed chemotherapy in patients aged 18 years and older, the role of adding ifosfamide/etoposide to vincristine/doxorubicin/cyclophosphamide for patients with metastatic disease, the data on and role of high-dose chemotherapy with autologous stem cell transplantation, maintenance therapy, and whole-lung irradiation. The data referenced are often limited to subgroup analyses and/or compiled from multiple sources. Although not intended to replace the clinical judgement of treating physicians, the guidelines are intended to provide clarity and recommendations for the upfront management of patients with ES. PLAIN LANGUAGE SUMMARY: Ewing sarcoma is a malignant tumor of bone and soft tissue that most often occurs in adolescents and young adults. For this review, the authors used the experience of the National Ewing Sarcoma Tumor Board, a multi-institution, multidisciplinary virtual tumor board that meets monthly to discuss complicated and challenging cases of Ewing sarcoma. Although not intended to replace the clinical judgement of treating physicians, the guidelines will focus on the development of consensus statements for the upfront management of patients with Ewing sarcoma.
Authors
Gupta, A; Riedel, RF; Shah, C; Borinstein, SC; Isakoff, MS; Chugh, R; Rosenblum, JM; Murphy, ES; Campbell, SR; Albert, CM; Zahler, S; Thomas, SM; Trucco, M
MLA Citation
Gupta, Ajay, et al. “Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board.” Cancer, July 2023. Pubmed, doi:10.1002/cncr.34942.
URI
https://scholars.duke.edu/individual/pub1586270
PMID
37403815
Source
pubmed
Published In
Cancer
Published Date
DOI
10.1002/cncr.34942
Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas.
Bone sarcomas are rare heterogeneous tumors that affect patients of all ages including children, adolescent young adults, and older adults. They include many aggressive subtypes and patient groups with poor outcomes, poor access to clinical trials, and lack of defined standard therapeutic strategies. Conventional chondrosarcoma remains a surgical disease, with no defined role for cytotoxic therapy and no approved targeted systemic therapies. Here, we discuss promising novel targets and strategies undergoing evaluation in clinical trials. Multiagent chemotherapy has greatly improved outcomes for patients with Ewing sarcoma (ES) and osteosarcoma, but management of those with high-risk or recurrent disease remains challenging and controversial. We describe the impact of international collaborative trials, such as the rEECur study, that aim to define optimal treatment strategies for those with recurrent, refractory ES, and evidence for high-dose chemotherapy with stem-cell support. We also discuss current and emerging strategies for other small round cell sarcomas, such as CIC-rearranged, BCOR-rearranged tumors, and the evaluation of emerging novel therapeutics and trial designs that may offer a new paradigm to improve survival in these aggressive tumors with notoriously bad (to the bone) outcomes.
Authors
Wood, GE; Graves, LA; Rubin, EM; Reed, DR; Riedel, RF; Strauss, SJ
MLA Citation
Wood, Georgina E., et al. “Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas.” Am Soc Clin Oncol Educ Book, vol. 43, May 2023, p. e390306. Pubmed, doi:10.1200/EDBK_390306.
URI
https://scholars.duke.edu/individual/pub1578549
PMID
37220319
Source
pubmed
Published In
Am Soc Clin Oncol Educ Book
Volume
43
Published Date
Start Page
e390306
DOI
10.1200/EDBK_390306
Hydropneumodissection-Assisted Cryoablation of Recurrent Sarcoma Adjacent to the Sciatic Nerve as a Limb-Sparing Alternative to Hindquarter Amputation.
Authors
MLA Citation
Sag, Alan A., et al. “Hydropneumodissection-Assisted Cryoablation of Recurrent Sarcoma Adjacent to the Sciatic Nerve as a Limb-Sparing Alternative to Hindquarter Amputation.” J Vasc Interv Radiol, vol. 34, no. 5, May 2023, pp. 923-926.e1. Pubmed, doi:10.1016/j.jvir.2022.12.469.
URI
https://scholars.duke.edu/individual/pub1561049
PMID
36584809
Source
pubmed
Published In
J Vasc Interv Radiol
Volume
34
Published Date
Start Page
923
End Page
926.e1
DOI
10.1016/j.jvir.2022.12.469
Dual energy analysis of TKI response in GIST - results of a prospective trial
Authors
MLA Citation
Hohenberger, Peter, et al. “Dual energy analysis of TKI response in GIST - results of a prospective trial.” Cancer Research, vol. 82, no. 12, 2022.
URI
https://scholars.duke.edu/individual/pub1571661
Source
wos-lite
Published In
Cancer Research
Volume
82
Published Date
Emerging predictive biomarkers in the management of bone and soft tissue sarcomas.
INTRODUCTION: Soft tissue and bone sarcomas are a heterogeneous group of malignancies, each with a unique biology and clinical course. As our understanding of individual sarcoma subtypes and their molecular landscapes increases, predictive biomarkers are emerging to improve patient selection for chemotherapies, targeted therapies, and immunotherapy approaches. AREAS COVERED: This review highlights predictive biomarkers rooted in molecular mechanisms of sarcoma biology, focusing on cell cycle regulation, DNA damage repair, and immune microenvironment interactions. We review CDK4/6 inhibitor predictive biomarkers, including CDKN2A loss, ATRX status, MDM2 levels, and Rb1 status. We discuss homologous recombination deficiency (HRD) biomarkers that predict vulnerability to DNA damage repair (DDR) pathway inhibitors, such as molecular signatures and functional HRD markers. We describe tertiary lymphoid structures and suppressive myeloid cells in the sarcoma immune microenvironment that may influence immunotherapy efficacy. EXPERT OPINION: While predictive biomarkers are not routinely used in sarcoma clinical practice currently, emerging biomarkers are being developed alongside clinical advancements. Novel therapies and predictive biomarkers will be essential for individualizing future approaches to sarcoma management and improving patient outcomes.
Authors
Haddox, CL; Riedel, RF
MLA Citation
Haddox, Candace L., and Richard F. Riedel. “Emerging predictive biomarkers in the management of bone and soft tissue sarcomas.” Expert Rev Anticancer Ther, vol. 23, no. 5, May 2023, pp. 495–502. Pubmed, doi:10.1080/14737140.2023.2200169.
URI
https://scholars.duke.edu/individual/pub1571671
PMID
37017995
Source
pubmed
Published In
Expert Rev Anticancer Ther
Volume
23
Published Date
Start Page
495
End Page
502
DOI
10.1080/14737140.2023.2200169

Associate Professor of Medicine
Contact:
Dept of Medicine, 25179 Morris Bldg, Durham, NC 27710
Duke Box 3198, Durham, NC 27710